IVA
Inventiva·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Bullish Abandoned Baby
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IVA
Inventiva S.A.
A clinical-stage biopharmaceutical company that developing oral small molecule therapies for non-alcoholic steatohepatitis
Biological Technology
--
07/10/2020
NASDAQ Stock Exchange
114
12-31
Depository Receipts (Ordinary Shares)
50 rue de Dijon, 21121 Daix France
--
Inventiva S.A. was established in 2011 and incorporated in 2016. The Company is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis or NASH, mucopolysaccharidases or MPS and other serious diseases with unmet medical needs. The company has established a pipeline supported by a discovery engine with an extensive proprietary molecular library, a wholly-owned R&D facility and a team with extensive expertise and experience in developing compounds targeting nuclear receptors, transcription factors and epigenetic regulation.
Company Financials
EPS
IVA has released its 2021 Q2 earnings. EPS was reported at -0.44, versus the expected 0, missing expectations. The chart below visualizes how IVA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
